<?xml version="1.0" encoding="UTF-8"?>
<paload id="" version="">
	<toplevel>
		<routedMedId>16772</routedMedId>
		<routedMedName>Enbrel subcutaneous</routedMedName>
		<routedGenericName>etanercept subcutaneous</routedGenericName>
		<etcIds>
			<etc_id/>
		</etcIds>
		<medIds>
			<medId>03.16772</medId>
			<medId>03.144657</medId>
		</medIds>
	</toplevel>
	<diagnoses>
		<diagnosis>
			<fqn>Rheumatoid Arthritis-Moderate to severely active</fqn>
			<age>
				<ageRangeType>ge</ageRangeType>
				<ageRangeMin>18</ageRangeMin>
				<ageRangeMax/>
				<ageRangeUnit>y</ageRangeUnit>
				<ageDesc/>
			</age>
			<gender>not specified</gender>
			<icd9>12.M06</icd9>
			<symbolic>Enbrel-RA-Mod</symbolic>
			<rating>labeledDx</rating>
			<genotype>
				<name></name>
			</genotype>
			<polymorphism>
				<name></name>
			</polymorphism>
			<subtype>
				<name></name>
			</subtype>
			<severity>
				<name>Moderate to severely active rheumatoid arthritis</name>
				<code></code>
				<dur></dur>
				<durUnit>nocode</durUnit>
			</severity>
			<prescribers>
				<prescriber>
					<name>Rheumatologist</name>
					<code>207RR0500X</code>
				</prescriber>
			</prescribers>
			<comorbidities>
				<comorbidity>
					<name>Hepatitis C</name>
					<code>12.B18.2</code>
					<severity_name/>
					<severity_code/>
					<subtype></subtype>
					<inclusion_exclusion>inclusion</inclusion_exclusion>
					<dur></dur>
					<durUnit>nocode</durUnit>
				</comorbidity>
				<comorbidity>
					<name>Infection</name>
					<code/>
					<severity_name>Serious</severity_name>
					<severity_code/>
					<subtype/>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
				<comorbidity>
					<name>Sepsis</name>
					<code>12.A41</code>
					<severity_name/>
					<severity_code/>
					<subtype/>
					<inclusion_exclusion>exclusion</inclusion_exclusion>
					<dur/>
					<durUnit>nocode</durUnit>
				</comorbidity>
			</comorbidities>
			<concurrenttherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>naive</typeName>
						<treatment> </treatment>
					</patientHxType>
					<preferredTherapy>
						<treatment> </treatment>
					</preferredTherapy>
				</criteriaSet>
			</concurrenttherapy>
			<triedtherapy>
				<criteriaSet>
					<patientHxType>
						<typeName>all</typeName>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name/>
								<codeValues/>
								<selectedListName/>
								<selectedListClassCode/>
							</treatmentLine>
						</treatment>
					</patientHxType>
					<preferredTherapy>
						<numRequired>any</numRequired>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Humira Pen subcutaneous</name>
								<codeValues>02.144769</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Humira subcutaneous</name>
								<codeValues>02.64713</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>true</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Remicade intravenous</name>
								<codeValues>02.16554</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Simponi ARIA intravenous</name>
								<codeValues>02.164798</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Simponi subcutaneous</name>
								<codeValues>02.152287</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Cimzia Powder for Reconstitution subcutaneous</name>
								<codeValues>02.154650</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Cimzia Starter Kit subcutaneous</name>
								<codeValues>02.154223</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Cimzia subcutaneous</name>
								<codeValues>02.150396</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Kineret subcutaneous</name>
								<codeValues>02.22175</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Actemra intravenous</name>
								<codeValues>02.153521</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Actemra subcutaneous</name>
								<codeValues>02.165329</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Orencia (with maltose) intravenous</name>
								<codeValues>02.94819</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Orencia subcutaneous</name>
								<codeValues>02.156713</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Rituxan intravenous</name>
								<codeValues>02.5206</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>drug</interventionType>
								<name>Xeljanz oral</name>
								<codeValues>02.162865</codeValues>
								<selectedListName/>
								<selectedListClassCode/>
								<durModifier>ge</durModifier>
								<dur>3</dur>
								<durUnit>m</durUnit>
								<timeFrame>ever</timeFrame>
								<numRequired>any</numRequired>
							</treatmentLine>
							<mustBeIneligible>false</mustBeIneligible>
							<documentationRequired>false</documentationRequired>
						</treatment>
					</preferredTherapy>
				</criteriaSet>
			</triedtherapy>
			<triedTherapyExclusion>
				<criteriaSet>
					<excludedTherapy>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.144769|02.64713</codeValues>
								<selectedListName>Anti-inflammatory Tumor Necrosis Factor Inhibiting Agnts,Sel</selectedListName>
								<selectedListClassCode>09.5708</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues/>
								<selectedListName>DMARD - Interleukin-1 Receptor Antagonist (IL-1Ra)</selectedListName>
								<selectedListClassCode>09.4541</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues/>
								<selectedListName>DMARD - Interleukin-6 (IL-6) Receptor Inhibitors, Monoclonal Antibody</selectedListName>
								<selectedListClassCode>09.6210</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues/>
								<selectedListName>DMARD - Antinflammatory, Select. costimulation modulator,T-cell Inhib.</selectedListName>
								<selectedListClassCode>09.5913</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues/>
								<selectedListName>DMARD - B Cell Targeted Agents</selectedListName>
								<selectedListClassCode>09.6488</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues/>
								<selectedListName>DMARD - Janus Kinase (JAK) Inhibitors</selectedListName>
								<selectedListClassCode>09.6387</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues/>
								<selectedListName>Live Vaccines</selectedListName>
								<selectedListClassCode>09.6421</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues/>
								<selectedListName>Anti-inflammatory - Interleukin-1 beta Blockers</selectedListName>
								<selectedListClassCode>09.6212</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues/>
								<selectedListName>Antipsoriatic Agents - MC Antibody, Human Interleukin 12/23 Inhibitors</selectedListName>
								<selectedListClassCode>09.6200</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
						<treatment>
							<treatmentLine>
								<option>OR</option>
								<interventionType>group</interventionType>
								<name/>
								<codeValues>02.165957</codeValues>
								<selectedListName>DMARD - Phosphodiesterase-4 (PDE4) Inhibitors</selectedListName>
								<selectedListClassCode>09.6436</selectedListClassCode>
								<timeFrame>nocode</timeFrame>
							</treatmentLine>
						</treatment>
					</excludedTherapy>
				</criteriaSet>
			</triedTherapyExclusion>
			<dosing>
				<text>50 mg subcutaneously once weekly.  Max: 50 mg weekly.</text>
				<text>Alternative: 25 mg subcutaneously twice weekly.  Max: 50 mg weekly.</text>
			</dosing>
			<instructions>
				<instruction/>
			</instructions>
			<qlimits>
				<qlimit>
					<medId>03.548882</medId>
					<initPerDayDesc>Not specified</initPerDayDesc>
					<initPerIntervalDesc>50 mg per week / 4 syringes per 28 days</initPerIntervalDesc>
					<renewPerDayDesc>Not specified</renewPerDayDesc>
					<renewPerIntervalDesc>50 mg per week / 4 syringes per 28 days</renewPerIntervalDesc>
				</qlimit>
				<qlimit>
					<medId>03.472035</medId>
					<initPerDayDesc>Not specified</initPerDayDesc>
					<initPerIntervalDesc>50 mg per week / 4 syringes per 28 days</initPerIntervalDesc>
					<renewPerDayDesc>Not specified</renewPerDayDesc>
					<renewPerIntervalDesc>50 mg per week / 4 syringes per 28 days</renewPerIntervalDesc>
				</qlimit>
				<qlimit>
					<medId>03.550723</medId>
					<initPerDayDesc>Not specified</initPerDayDesc>
					<initPerIntervalDesc>50 mg per week / 8 syringes per 28 days</initPerIntervalDesc>
					<renewPerDayDesc>Not specified</renewPerDayDesc>
					<renewPerIntervalDesc>50 mg per week / 8 syringes per 28 days</renewPerIntervalDesc>
				</qlimit>
				<qlimit>
					<medId>03.273372</medId>
					<initPerDayDesc>Not specified</initPerDayDesc>
					<initPerIntervalDesc>50 mg per week / 8 kits (vials) per 28 days</initPerIntervalDesc>
					<renewPerDayDesc>Not specified</renewPerDayDesc>
					<renewPerIntervalDesc>50 mg per week / 8 kits (vials) per 28 days</renewPerIntervalDesc>
				</qlimit>
			</qlimits>
			<durations>
				<initialDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</initialDur>
				<renewalDur>
					<dur>1</dur>
					<durUnit>y</durUnit>
				</renewalDur>
				<overallMax>
					<dur>Not specified</dur>
					<durUnit>nocode</durUnit>
				</overallMax>
			</durations>
			<references>
				<reference>Enbrel [package insert].  Thousand Oaks, CA: Amgen Inc; 2013</reference>
				<reference>Singh JA, Furst DE, Bharat A, et al.  2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis.  Arthritis Care &amp; Research. 2012; 64: 625-39. DOI 10.1002/acr.21641</reference>
				<reference>Saag KG, Teng GG, Patkar NM, et al.  American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis.  Arthritis Care &amp; Research.  2008; 59: 762-84.  DOI 10.1002/art.23721</reference>
				<reference>Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000; 356: 385-90.</reference>
			</references>
			<precautions>
				<precaution>
					<text/>
					<severity/>
				</precaution>
			</precautions>
		</diagnosis>
	</diagnoses>
	<precautions>
		<geriatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</geriatric>
		<pregnancy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pregnancy>
		<pediatric>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</pediatric>
		<lactation>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</lactation>
		<allergy>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</allergy>
		<sideEffect>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</sideEffect>
		<drugDisease>
			<caution>
				<drug/>
				<severity/>
				<text/>
			</caution>
		</drugDisease>
	</precautions>
	<lists>
		<listDef>
			<name>Anti-inflammatory Tumor Necrosis Factor Inhibiting Agnts,Sel</name>
			<codeValue>09.5708</codeValue>
			<listType>class</listType>
			<listItem>
				<name>Humira Pen subcutaneous</name>
				<codeValue>02.144769</codeValue>
			</listItem>
			<listItem>
				<name>Humira subcutaneous</name>
				<codeValue>02.64713</codeValue>
			</listItem>
			<listItem>
				<name>Cimzia Powder for Reconstitution subcutaneous</name>
				<codeValue>02.154650</codeValue>
			</listItem>
			<listItem>
				<name>Cimzia Starter Kit subcutaneous</name>
				<codeValue>02.154223</codeValue>
			</listItem>
			<listItem>
				<name>Cimzia subcutaneous</name>
				<codeValue>02.150396</codeValue>
			</listItem>
			<listItem>
				<name>Simponi ARIA intravenous</name>
				<codeValue>02.164798</codeValue>
			</listItem>
			<listItem>
				<name>Simponi subcutaneous</name>
				<codeValue>02.152287</codeValue>
			</listItem>
			<listItem>
				<name>Remicade intravenous</name>
				<codeValue>02.16554</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>DMARD - Interleukin-1 Receptor Antagonist (IL-1Ra)</name>
			<codeValue>09.4541</codeValue>
			<listType>class</listType>
			<listItem>
				<name>Kineret subcutaneous</name>
				<codeValue>02.22175</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>DMARD - Interleukin-6 (IL-6) Receptor Inhibitors, Monoclonal Antibody</name>
			<codeValue>09.6210</codeValue>
			<listType>class</listType>
			<listItem>
				<name>Actemra intravenous</name>
				<codeValue>02.153521</codeValue>
			</listItem>
			<listItem>
				<name>Actemra subcutaneous</name>
				<codeValue>02.165329</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>DMARD - Antinflammatory, Select. costimulation modulator,T-cell Inhib.</name>
			<codeValue>09.5913</codeValue>
			<listType>class</listType>
			<listItem>
				<name>Orencia (with maltose) intravenous</name>
				<codeValue>02.94819</codeValue>
			</listItem>
			<listItem>
				<name>Orencia subcutaneous</name>
				<codeValue>02.156713</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>DMARD - B Cell Targeted Agents</name>
			<codeValue>09.6488</codeValue>
			<listType>class</listType>
			<listItem>
				<name>Rituxan intravenous</name>
				<codeValue>02.5206</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>DMARD - Janus Kinase (JAK) Inhibitors</name>
			<codeValue>09.6387</codeValue>
			<listType>class</listType>
			<listItem>
				<name>Xeljanz oral</name>
				<codeValue>02.162865</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>Live Vaccines</name>
			<codeValue>09.6421</codeValue>
			<listType>class</listType>
			<listItem>
				<name>adenovirus vaccine live type-4 and 7 oral</name>
				<codeValue>02.164880</codeValue>
			</listItem>
			<listItem>
				<name>adenovirus vaccine live type-4 oral</name>
				<codeValue>02.164878</codeValue>
			</listItem>
			<listItem>
				<name>adenovirus vaccine live type-7 oral</name>
				<codeValue>02.164879</codeValue>
			</listItem>
			<listItem>
				<name>Theracys intravesical</name>
				<codeValue>02.15402</codeValue>
			</listItem>
			<listItem>
				<name>Tice BCG intravesical</name>
				<codeValue>02.94519</codeValue>
			</listItem>
			<listItem>
				<name>BCG vaccine, live (PF) percutaneous</name>
				<codeValue>02.154546</codeValue>
			</listItem>
			<listItem>
				<name>Flumist Quad 2014-2015 nasal</name>
				<codeValue>02.166545</codeValue>
			</listItem>
			<listItem>
				<name>M-M-R II (PF) subcutaneous</name>
				<codeValue>02.150450</codeValue>
			</listItem>
			<listItem>
				<name>ProQuad (PF) subcutaneous</name>
				<codeValue>02.94107</codeValue>
			</listItem>
			<listItem>
				<name>Rotarix oral</name>
				<codeValue>02.150652</codeValue>
			</listItem>
			<listItem>
				<name>RotaTeq Vaccine oral</name>
				<codeValue>02.95020</codeValue>
			</listItem>
			<listItem>
				<name>Vivotif Berna Vaccine oral</name>
				<codeValue>02.9755</codeValue>
			</listItem>
			<listItem>
				<name>Varivax (PF) subcutaneous</name>
				<codeValue>02.11314</codeValue>
			</listItem>
			<listItem>
				<name>YF-Vax (PF) subcutaneous</name>
				<codeValue>02.150614</codeValue>
			</listItem>
			<listItem>
				<name>ZOSTAVAX  subcutaneous</name>
				<codeValue>02.144377</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>Anti-inflammatory - Interleukin-1 beta Blockers</name>
			<codeValue>09.6212</codeValue>
			<listType>class</listType>
			<listItem>
				<name>Ilaris (PF) subcutaneous</name>
				<codeValue>02.152794</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>Antipsoriatic Agents - MC Antibody, Human Interleukin 12/23 Inhibitors</name>
			<codeValue>09.6200</codeValue>
			<listType>class</listType>
			<listItem>
				<name>Stelara subcutaneous</name>
				<codeValue>02.153035</codeValue>
			</listItem>
		</listDef>
		<listDef>
			<name>DMARD - Phosphodiesterase-4 (PDE4) Inhibitors</name>
			<codeValue>09.6436</codeValue>
			<listType>class</listType>
			<listItem>
				<name>Otezla Starter oral</name>
				<codeValue>02.165957</codeValue>
			</listItem>
			<listItem>
				<name>Otezla oral</name>
				<codeValue>02.165956</codeValue>
			</listItem>
		</listDef>
	</lists>
</paload>
